000			02036 a2200601 4500
005			20250515112530.0
264		0	_c20080807
008			200808s 0 0 eng d
022			_a1476-5594
024	7		_a10.1038/onc.2008.49 _2doi
040			_aNLM _beng _cNLM
100	1		_aSteelman, L S
245	0	0	_aSuppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. _h[electronic resource]
260			_bOncogene _cJul 2008
300			_a4086-95 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAmino Acid Substitution
650	0	4	_aAntibiotics, Antineoplastic _xagonists
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCell Line, Tumor
650	0	4	_aDoxorubicin _xagonists
650	0	4	_aDrug Resistance, Neoplasm _xdrug effects
650	0	4	_aDrug Synergism
650	0	4	_aFemale
650	0	4	_aGene Expression
650	0	4	_aHumans
650	0	4	_aMutation, Missense
650	0	4	_aPTEN Phosphohydrolase _xantagonists & inhibitors
650	0	4	_aProtein Kinases _xgenetics
650	0	4	_aProto-Oncogene Proteins c-akt _xgenetics
650	0	4	_aRibosomal Protein S6 Kinases, 70-kDa _xgenetics
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSirolimus _xagonists
650	0	4	_aTOR Serine-Threonine Kinases
650	0	4	_aTransfection
700	1		_aNavolanic, P M
700	1		_aSokolosky, M L
700	1		_aTaylor, J R
700	1		_aLehmann, B D
700	1		_aChappell, W H
700	1		_aAbrams, S L
700	1		_aWong, E W T
700	1		_aStadelman, K M
700	1		_aTerrian, D M
700	1		_aLeslie, N R
700	1		_aMartelli, A M
700	1		_aStivala, F
700	1		_aLibra, M
700	1		_aFranklin, R A
700	1		_aMcCubrey, J A
773	0		_tOncogene _gvol. 27 _gno. 29 _gp. 4086-95
856	4	0	_uhttps://doi.org/10.1038/onc.2008.49 _zAvailable from publisher's website
999			_c17834887 _d17834887